tions. Central nervous system (CNS) gp 130 is a major sialylated glycoprotein component of the CNS which is detectable at the synapse. This molecule is, however, heavily glycosylated and is detectable as a component of myelin (P. R. Gordon-Weeks, personal communication). Both immunocytochemical studies and Western blot analysis show that the present antigens are not myelin associated. Furthermore, CNS gp 130 contains considerably more carbohydrate than the M, 130000 and 117000 antigens recognized by our mab. Psds are selectively enriched in glycoproteins of M, 1 16 000 and 110000. The M, of these species is shifted by 15000 and 2000, respectively, after removal of con-Abinding oligosaccharides with endoglycosidase H [ 11. Furthermore, comparison of Western blots developed with mab psd gp 130 and with biotinylated con A (Fig. 3) show that the M, 130000 and 117000 bands recognized by the antibody are of significantly higher M, than the 1 16 000 and 1 10 000 species described by Curd [ 11.
We thus conclude that the M , 130 000 and 1 17 000 glycoproteins recognized by map psd gpl30 are novel molecular species. Their subcellular distribution indicates that they are not solely membrane glycoproteins, but are likely to be true components of mammalian psds. However, both the subcellular distribution and immunocytochemical studies suggest that neither species is psd specific. The failure to observe clear immunocytochemical staining of psds suggests that the epitope may be masked in the junctional region. For example, if the epitope is located on a region of the molecule which interacts with the densely packed psd, then it would not be expected to be accessible to the antibody. Initial results suggest that tryptic digestion of cultured fetal forebrain neurones does not result in any loss of immunoreactivity by either the M, 130 000 or 1 17 000 glycoproteins. This is in contrast to the complete loss of immunoreactivity observed following tryptic digestion of solubilized SM.
It is anticipated that mab psd gpl30 will be useful for further characterization of both these novel psd-enriched glycoproteins and for studying their possible roles in psd formation and function. Duchenne muscular dystrophy (DMD) affects approximately 1 in 3500 live male births and is characterized by progressive muscle weakness and premature death. Patients arc usually in a wheelchair by the age of 12 and die in their early twenties. Additionally, 20-30% of DMD patients suffer from non-progressive mental retardation. Becker muscular dystrophy (BMD) results from a defect in the same gene, but is a less severe and rarer allele, affecting 1 in 30000 boys who have a wide variation in both progression and onset of the disease.
The DMD gene has recently been identified and encodes a 427 kDa protein, dystrophin [l] . Antibodies raised to fusion proteins derived from dystrophin cDNA fragments are used to study the protein both by immunocytochemistry and Western blot analysis. In this way, DMD patients have been shown to have no dystrophin, whereas BMD patients possess an abnormal protein of either altered molecular mass or reduced abundance [2] . The mdx mouse has a point mutaAbbreviations used: DMD. Duchenne muscular dystrophy; BMD, Becker muscular dystrophy. tion in the DMD gene and has no dystrophin, but exhibits little or no signs of muscle weakness. It can therefore be used as an animal model for some aspects of the disease.
Dystrophin mRNA is found only in skclctal, smooth and cardiac muscle and in brain, the levels in brain being -l/lOth that of muscle 131. RNAase protection assays and polymerase chain reaction techniques have demonstrated the presence of several isoforms of the DMD transcript produced either by the use of alternative promoters, which generate transcripts in muscle and brain differing in the first exon [4], or by alternative splicing at the 3' end o f the gene [ 51. Dystrophin antibodies localize to the sarcolemmal membrane in skeletal muscle, but the location in other tissues is unknown. On Western blots, dystrophin immunorcactivity appears as a triplet of -400 kDa in skeletal and cardiac muscle and as a doublet in smooth muscle. In brain, a single band is seen at -400 kDa, and using an antibody raised t o the N-terminal region of the protein, a strongly immunoreactive protein of -230 kDa can be detected. The 230 kDa protein is also seen in mdx brain, suggesting that it is not a product of the DMD gene, but may instead be due to crossreactivity of the antiserum with a dystrophin-like protein.
Since the amino acid sequence of dystrophin predicts a spectrin-like region of triple-helical repeats [ 1 I and brain spectrin proteins have a molecular mass of 235/240 kDa, the possibility of cross-reactivity with spectrin must also be considered. It seems unlikely that the 230 kDa protein detected by the I loffrnan antibody is either o f the two forms o f hrain spectrin presently characterized. T h e pattern o f immunostaining seen in the cerebellum is very different from that seen with fodrin antibodies and, although it is similar to the 240/23SE form. it seems likely that the dystrophin 230 kDa protein is present in the axons o f neurons, whereas the 240/235E brain spcctrin is not. However. attempts t o purify the dystrophin 730 kDa protein suggest that it may he very similar t o spectrin, particularly in the way it associates with the rncnibrane (i.e. it appears t o be loosely attached and can therefore be extracted in low-salt conditions.) Dystrophin seems t o be much more tightly associated with the membrane a n d is relatively insoluhlc requiring either
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